Investigations performed on other cancer types demonstrated PIK3R1 copy number loss in 23% of breast cancers, as well as in 24% and 36% of primary and metastatic prostate cancers, respectively [17,18]. This evidence concerns the gene PIK3R1 and breast carcinoma.